Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer
Clinical trial NCT05085626 · UNKNOWN
Trial details
- NCT number
- NCT05085626
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-02-08
- Primary completion
- 2023-10-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.